Novavax Archives | Page 2 of 6

Home / Posts tagged Novavax (Page 2)

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 7 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. This follows an agreement in principle that was [...]

Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

GAITHERSBURG, Md., Dec. 28 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company’s COVID-19 vaccine candidate. The trial builds [...]

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine

GAITHERSBURG, Md., Dec. 16 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. Currently in Phase 3 clinical testing in [...]

Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors

GAITHERSBURG, Md., Dec. 9 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Ms. McGlynn brings extensive pharmaceutical industry, vaccine and non-profit experience to her role on the Novavax [...]

Novavax Announces COVID-19 Vaccine Clinical Development Progress

GAITHERSBURG, Md., Nov. 30 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix‑M™. [...]

Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020

GAITHERSBURG, Md., Nov. 10 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, will host a conference call for the investment community to pose questions related to the Company’s third quarter 2020 financial and operating results. The call will be held because of technical issues [...]

Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates

GAITHERSBURG, Md., Nov. 9 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates to its leadership team, including the appointment of Gregory F. Covino as Executive Vice President and Chief Financial Officer (CFO). Executive Vice President John Trizzino, who previously served as CFO, will now [...]

Novavax Reports Third Quarter 2020 Financial and Operational Results

GAITHERSBURG, Md., Nov. 9 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2020. “Novavax continued to deliver remarkable progress this quarter, with our most notable achievement being the initiation of [...]

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

GAITHERSBURG, Md., Nov. 9 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made [...]

Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine

GAITHERSBURG, Md., Nov. 4 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community. “This [...]